PL2806028T3 - Związki i sposoby zmniejszania rekrutacji i/lub migracji komórek polimorfojądrowych - Google Patents

Związki i sposoby zmniejszania rekrutacji i/lub migracji komórek polimorfojądrowych

Info

Publication number
PL2806028T3
PL2806028T3 PL14154643T PL14154643T PL2806028T3 PL 2806028 T3 PL2806028 T3 PL 2806028T3 PL 14154643 T PL14154643 T PL 14154643T PL 14154643 T PL14154643 T PL 14154643T PL 2806028 T3 PL2806028 T3 PL 2806028T3
Authority
PL
Poland
Prior art keywords
recruitment
migration
compounds
reducing
methods
Prior art date
Application number
PL14154643T
Other languages
English (en)
Inventor
Charlotte Admyre
Lars-Göran Axelsson
Stein Oliver Von
Arezou Zargari
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of PL2806028T3 publication Critical patent/PL2806028T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL14154643T 2008-11-04 2009-10-28 Związki i sposoby zmniejszania rekrutacji i/lub migracji komórek polimorfojądrowych PL2806028T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11128408P 2008-11-04 2008-11-04
SE0802338 2008-11-04
EP14154643.2A EP2806028B1 (en) 2008-11-04 2009-10-28 Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells

Publications (1)

Publication Number Publication Date
PL2806028T3 true PL2806028T3 (pl) 2017-11-30

Family

ID=42153087

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14154643T PL2806028T3 (pl) 2008-11-04 2009-10-28 Związki i sposoby zmniejszania rekrutacji i/lub migracji komórek polimorfojądrowych

Country Status (11)

Country Link
US (2) US8877724B2 (pl)
EP (2) EP2342341B1 (pl)
JP (1) JP5749651B2 (pl)
AU (1) AU2009311748B2 (pl)
CA (1) CA2778938C (pl)
DK (2) DK2342341T3 (pl)
ES (2) ES2464731T3 (pl)
HR (1) HRP20171360T1 (pl)
LT (1) LT2806028T (pl)
PL (1) PL2806028T3 (pl)
WO (1) WO2010053430A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2778961C (en) * 2008-11-04 2019-06-18 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the cns
WO2012084991A1 (en) 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
EP2468867A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Methods for identifying biologically active oligonucleotides capable of modulating the immune system
CA2859698C (en) 2010-12-21 2021-03-02 Index Pharmaceuticals Ab Methods for identifying biologically active oligonucleotides capable of modulating the immune system
EP2468866A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Biologically active oligonucleotides capable of modulating the immune system
US9873878B2 (en) * 2015-03-30 2018-01-23 University Of Louisville Research Foundation, Inc. Compositions and methods for use in treating silicosis and lung cancer
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
JP2021131228A (ja) * 2018-04-27 2021-09-09 国立大学法人 東京大学 難治性喘息の予防又は治療剤をスクリーニングする方法、及び難治性喘息の予防又は治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
SE9602300D0 (sv) * 1996-06-11 1996-06-11 Karolinska Innovations Ab New composition and methods
PT1163204E (pt) 1999-03-18 2005-11-30 Brigham & Womens Hospital Compostos a base de lipoxina e sua utilizacao
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
WO2004110478A1 (en) * 2003-06-19 2004-12-23 Ctt Cancer Targeting Technologies Oy Inhibitors of cell migration
SE0400399D0 (sv) 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
US20090306190A1 (en) * 2005-09-09 2009-12-10 Mary Stenzel-Poore Neuroprotectants
WO2007030580A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
WO2008136748A1 (en) * 2007-05-04 2008-11-13 Index Pharmaceuticals Ab Tumour growth inhibitory compounds and methods of their use
US20110280934A1 (en) 2008-11-04 2011-11-17 Asa Karlsson Increased Expression of Specific Antigens
CA2778961C (en) 2008-11-04 2019-06-18 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the cns

Also Published As

Publication number Publication date
HRP20171360T1 (hr) 2017-11-03
CA2778938A1 (en) 2010-05-14
LT2806028T (lt) 2017-12-11
DK2806028T3 (en) 2017-10-09
DK2342341T3 (da) 2014-05-12
EP2342341A1 (en) 2011-07-13
US10046006B2 (en) 2018-08-14
AU2009311748B2 (en) 2014-08-21
CA2778938C (en) 2019-07-02
WO2010053430A1 (en) 2010-05-14
JP2012507307A (ja) 2012-03-29
EP2806028B1 (en) 2017-07-12
JP5749651B2 (ja) 2015-07-15
EP2342341B1 (en) 2014-03-05
EP2806028A2 (en) 2014-11-26
EP2342341A4 (en) 2013-01-09
US20150099799A1 (en) 2015-04-09
EP2806028A3 (en) 2015-03-11
US8877724B2 (en) 2014-11-04
ES2464731T3 (es) 2014-06-03
ES2641751T3 (es) 2017-11-13
US20110301225A1 (en) 2011-12-08
AU2009311748A1 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
HRP20171360T1 (hr) Spojevi i postupci smanjivanja novačenja i/ili seljenja polimorfonuklearnih stanica
IL267138A (en) Improved composition of cells and methods for its preparation
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
EP2285217A4 (en) CONNECTIONS TO IMPROVE LEARNING AND MEMORY
HK1153946A1 (en) Oxymethylene aryl compounds and uses thereof
IL209740A0 (en) Methods for the production of ips cells using non-viral approach
IL208004A0 (en) Compounds and methods for reducing uric acid
EP2171096A4 (en) CARBOXYL REPAIRS-1-POLYMORPHISMS AND METHOD FOR THEIR USE
EP2464652A4 (en) HAFNIUM AND ZIRCONIUM-CONTAINING PRECEDENTS AND METHOD OF USE THEREOF
EP2069477A4 (en) CHEMOREPULSION OF CELLS
EP2341935A4 (en) METHODS FOR IMPROVING BETA CELL FUNCTION
EP2318508A4 (en) DETERMINATION OF RNA INTEGRITY
HK1169993A1 (en) Hsl inhibitors useful in the treatment of diabetes hsl
ZA201000381B (en) Use of yeast cell walls for treating and/or preventing hyper-insulinemia
HK1151190A1 (en) Methods of treating scleroderma
IL211567A0 (en) Use of stem cells to prevent neuronal dieback
EP2488642A4 (en) COMPOSITIONS AND METHODS FOR TREATING THE MEDICINAL-INDUCED HAND-FOOT SYNDROME
PL2446276T3 (pl) Sposoby określania stanu onkogennego komórki, ich zastosowania i sposoby leczenia nowotworu
IL243809A0 (en) Process for the production of γ-ketosulfide compound and γ-ketosulfide compounds
EP2121042A4 (en) COMPOUNDS AND METHOD FOR THE DETECTION OF CELLS
EP2243773A4 (en) PLATINUM COMPLEX CONNECTION AND ITS USE
EP2140000A4 (en) METHOD FOR IMPROVING MIGRATION OF PRECURSOR NEURAL CELLS
HK1157387A1 (en) Use of hsa-producing cells
GB0805670D0 (en) Increasing the plasticity of stem cells
TWM401709U (en) Screw structure and driver thereof